Jane Chung | BiotechTV

top of page

Sutro Biopharma is developing next generation antibody-drug conjugates, including dual payload ADCs. CEO Jane Chung walks us through their programs

She describes a dual payload ADC targeting TROP2 that is partnered with Astellas, as well as internal programs targeting tissue factor (currently in the clinic), integrin β6, and a dual payload ADC targeting PTK7.

Company News

2 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

Sutro Biopharma is developing next generation antibody-drug conjugates, including dual payload ADCs. CEO Jane Chung walks us through their programs

Follow BiotechTV

Sponsors

Sponsor Spotlight